194 related articles for article (PubMed ID: 30523157)
1. Functional genomic characterization of a synthetic anti-HER3 antibody reveals a role for ubiquitination by RNF41 in the anti-proliferative response.
Turowec JP; Lau EWT; Wang X; Brown KR; Fellouse FA; Jawanda KK; Pan J; Moffat J; Sidhu SS
J Biol Chem; 2019 Jan; 294(4):1396-1409. PubMed ID: 30523157
[TBL] [Abstract][Full Text] [Related]
2. Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer.
Ogier C; Colombo PE; Bousquet C; Canterel-Thouennon L; Sicard P; Garambois V; Thomas G; Gaborit N; Jarlier M; Pirot N; Pugnière M; Vie N; Gongora C; Martineau P; Robert B; Pèlegrin A; Chardès T; Larbouret C
Cancer Lett; 2018 Sep; 432():227-236. PubMed ID: 29935372
[TBL] [Abstract][Full Text] [Related]
3. Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers.
Osada T; Hartman ZC; Wei J; Lei G; Hobeika AC; Gwin WR; Diniz MA; Spector N; Clay TM; Chen W; Morse MA; Lyerly HK
Breast Cancer Res; 2018 Aug; 20(1):90. PubMed ID: 30092835
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Tumor Cell Growth and Cancer Stem Cell Expansion by a Bispecific Antibody Targeting EGFR and HER3.
Rau A; Lieb WS; Seifert O; Honer J; Birnstock D; Richter F; Aschmoneit N; Olayioye MA; Kontermann RE
Mol Cancer Ther; 2020 Jul; 19(7):1474-1485. PubMed ID: 32430487
[TBL] [Abstract][Full Text] [Related]
5. The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation.
Le Clorennec C; Lazrek Y; Dubreuil O; Larbouret C; Poul MA; Mondon P; Melino G; Pèlegrin A; Chardès T
Oncotarget; 2016 Jun; 7(24):37013-37029. PubMed ID: 27203743
[TBL] [Abstract][Full Text] [Related]
6. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor peptide vaccination induces cross-reactive immunity to human EGFR, HER2, and HER3.
Doyle HA; Koski RA; Bonafé N; Bruck RA; Tagliatela SM; Gee RJ; Mamula MJ
Cancer Immunol Immunother; 2018 Oct; 67(10):1559-1569. PubMed ID: 30056598
[TBL] [Abstract][Full Text] [Related]
8. A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.
Xiao Z; Carrasco RA; Schifferli K; Kinneer K; Tammali R; Chen H; Rothstein R; Wetzel L; Yang C; Chowdhury P; Tsui P; Steiner P; Jallal B; Herbst R; Hollingsworth RE; Tice DA
Mol Cancer Ther; 2016 Apr; 15(4):689-701. PubMed ID: 26880266
[TBL] [Abstract][Full Text] [Related]
9. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
[TBL] [Abstract][Full Text] [Related]
10. 10D1F, an Anti-HER3 Antibody that Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models.
Thakkar D; Sancenon V; Taguiam MM; Guan S; Wu Z; Ng E; Paszkiewicz KH; Ingram PJ; Boyd-Kirkup JD
Mol Cancer Ther; 2020 Feb; 19(2):490-501. PubMed ID: 31911530
[TBL] [Abstract][Full Text] [Related]
11. The E3 ubiquitin ligase NEDD4 negatively regulates HER3/ErbB3 level and signaling.
Huang Z; Choi BK; Mujoo K; Fan X; Fa M; Mukherjee S; Owiti N; Zhang N; An Z
Oncogene; 2015 Feb; 34(9):1105-15. PubMed ID: 24662824
[TBL] [Abstract][Full Text] [Related]
12. RG7116, a therapeutic antibody that binds the inactive HER3 receptor and is optimized for immune effector activation.
Mirschberger C; Schiller CB; Schräml M; Dimoudis N; Friess T; Gerdes CA; Reiff U; Lifke V; Hoelzlwimmer G; Kolm I; Hopfner KP; Niederfellner G; Bossenmaier B
Cancer Res; 2013 Aug; 73(16):5183-94. PubMed ID: 23780344
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer.
Luhtala S; Staff S; Kallioniemi A; Tanner M; Isola J
BMC Cancer; 2018 Oct; 18(1):1045. PubMed ID: 30367623
[TBL] [Abstract][Full Text] [Related]
14. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
Lee-Hoeflich ST; Crocker L; Yao E; Pham T; Munroe X; Hoeflich KP; Sliwkowski MX; Stern HM
Cancer Res; 2008 Jul; 68(14):5878-87. PubMed ID: 18632642
[TBL] [Abstract][Full Text] [Related]
15. Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3.
Le Clorennec C; Bazin H; Dubreuil O; Larbouret C; Ogier C; Lazrek Y; Garambois V; Poul MA; Mondon P; Barret JM; Mathis G; Prost JF; Pèlegrin A; Chardès T
Mol Cancer Ther; 2017 Jul; 16(7):1312-1323. PubMed ID: 28507002
[TBL] [Abstract][Full Text] [Related]
16. Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck Cancers.
Li C; Huang S; Armstrong EA; Francis DM; Werner LR; Sliwkowski MX; van der Kogel A; Harari PM
Mol Cancer Ther; 2015 Sep; 14(9):2049-59. PubMed ID: 26141946
[TBL] [Abstract][Full Text] [Related]
17. A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization.
Hashimoto Y; Koyama K; Kamai Y; Hirotani K; Ogitani Y; Zembutsu A; Abe M; Kaneda Y; Maeda N; Shiose Y; Iguchi T; Ishizaka T; Karibe T; Hayakawa I; Morita K; Nakada T; Nomura T; Wakita K; Kagari T; Abe Y; Murakami M; Ueno S; Agatsuma T
Clin Cancer Res; 2019 Dec; 25(23):7151-7161. PubMed ID: 31471314
[TBL] [Abstract][Full Text] [Related]
18. HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models.
Thomas G; Chardès T; Gaborit N; Mollevi C; Leconet W; Robert B; Radosevic-Robin N; Penault-Llorca F; Gongora C; Colombo PE; Lazrek Y; Bras-Goncalves R; Savina A; Azria D; Bazin H; Pèlegrin A; Larbouret C
Oncotarget; 2014 Aug; 5(16):7138-48. PubMed ID: 25216528
[TBL] [Abstract][Full Text] [Related]
19. Examination of HER3 targeting in cancer using monoclonal antibodies.
Gaborit N; Abdul-Hai A; Mancini M; Lindzen M; Lavi S; Leitner O; Mounier L; Chentouf M; Dunoyer S; Ghosh M; Larbouret C; Chardès T; Bazin H; Pèlegrin A; Sela M; Yarden Y
Proc Natl Acad Sci U S A; 2015 Jan; 112(3):839-44. PubMed ID: 25564668
[TBL] [Abstract][Full Text] [Related]
20. Novel association of DJ-1 with HER3 potentiates HER3 activation and signaling in cancer.
Zhang S; Mukherjee S; Fan X; Salameh A; Mujoo K; Huang Z; Li L; To'a Salazar G; Zhang N; An Z
Oncotarget; 2016 Oct; 7(40):65758-65769. PubMed ID: 27582551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
